Our top pick for
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Aptose Biosciences Inc is a biotechnology business based in the US. Aptose Biosciences shares (APTO) are listed on the NASDAQ and all prices are listed in US Dollars. Aptose Biosciences employs 31 staff and has a market cap (total outstanding shares value) of USD$501.1 million.
Since the stock market crash in March caused by coronavirus, Aptose Biosciences's share price has had significant negative movement.
Its last market close was USD$5.64, which is 34.80% down on its pre-crash value of USD$8.65 and 32.08% up on the lowest point reached during the March crash when the shares fell as low as USD$4.27.
If you had bought USD$1,000 worth of Aptose Biosciences shares at the start of February 2020, those shares would have been worth USD$742.28 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$794.39.
|Latest market close||USD$5.64|
|52-week range||USD$1.82 - USD$9.2525|
|50-day moving average||USD$5.876|
|200-day moving average||USD$6.3159|
|Wall St. target price||USD$4.72|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-0.594|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2020-11-24)||-9.32%|
|1 month (2020-10-30)||25.61%|
|3 months (2020-09-01)||-8.29%|
|6 months (2020-06-01)||-25.98%|
|1 year (2019-11-29)||108.12%|
|2 years (2018-11-30)||146.61%|
|3 years (2017-12-01)||180.60%|
|5 years (2015-12-01)||87.38%|
|Gross profit TTM||USD$0|
|Return on assets TTM||-43.14%|
|Return on equity TTM||-74.05%|
|Market capitalisation||USD$501.1 million|
TTM: trailing 12 months
There are currently 2.5 million Aptose Biosciences shares held short by investors – that's known as Aptose Biosciences's "short interest". This figure is 5.2% up from 2.4 million last month.
There are a few different ways that this level of interest in shorting Aptose Biosciences shares can be evaluated.
Aptose Biosciences's "short interest ratio" (SIR) is the quantity of Aptose Biosciences shares currently shorted divided by the average quantity of Aptose Biosciences shares traded daily (recently around 949141.19850187). Aptose Biosciences's SIR currently stands at 2.67. In other words for every 100,000 Aptose Biosciences shares traded daily on the market, roughly 2670 shares are currently held short.
However Aptose Biosciences's short interest can also be evaluated against the total number of Aptose Biosciences shares, or, against the total number of tradable Aptose Biosciences shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Aptose Biosciences's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Aptose Biosciences shares in existence, roughly 30 shares are currently held short) or 0.0292% of the tradable shares (for every 100,000 tradable Aptose Biosciences shares, roughly 29 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Aptose Biosciences.
Find out more about how you can short Aptose Biosciences stock.
We're not expecting Aptose Biosciences to pay a dividend over the next 12 months.
Aptose Biosciences's shares were split on a 1:12 basis on 6 October 2014. So if you had owned 12 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Aptose Biosciences shares – just the quantity. However, indirectly, the new 1100% higher share price could have impacted the market appetite for Aptose Biosciences shares which in turn could have impacted Aptose Biosciences's share price.
Over the last 12 months, Aptose Biosciences's shares have ranged in value from as little as $1.82 up to $9.2525. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Aptose Biosciences's is 0.8283. This would suggest that Aptose Biosciences's shares are less volatile than average (for this exchange).
Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in the United States. Its clinical programs is APTO-253, which is a Phase 1b clinical trial for the treatment of patients with relapsed/refractory blood cancers, including acute myeloid leukemia and high-risk myelodysplastic syndrome. It has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a bioavailable non-covalent small molecule that is in Phase 1a/b clinical trial for the treatment of patients with relapsed/refractory acute myeloid leukemia and various B-cell malignancies. The company also has an agreement with OHM Oncology for the development, manufacture, and commercialization of APL-581 for the treatment of hematologic malignancies, as well as related molecules. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Toronto, Canada.
Everything we know about the WorldRemit IPO, plus information on how to buy in.
Everything we know about the Jowell Global IPO, plus information on how to buy in.
Steps to owning and managing AIRG, with 24-hour and historical pricing before you buy.
Steps to owning and managing AMTX, with 24-hour and historical pricing before you buy.
Steps to owning and managing ACER, with 24-hour and historical pricing before you buy.
Steps to owning and managing WST, with 24-hour and historical pricing before you buy.
Steps to owning and managing VRNA, with 24-hour and historical pricing before you buy.
Steps to owning and managing OLED, with 24-hour and historical pricing before you buy.
Steps to owning and managing RARE, with 24-hour and historical pricing before you buy.
Steps to owning and managing TRVI, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.